Rare diseases
Investigational molecules
Locations
Study of Nivolumab and Relatlimab for Adults with Advanced or Metastatic Soft-Tissue Sarcoma
FranceStudy on the Safety of Radiation and Nivolumab for Patients with Esophageal Cancer
NorwayStudy of Vusolimogene Oderparepvec and Nivolumab for Patients with Solid Tumors
FranceStudy of Nivolumab for Patients with Esophageal Cancer Undergoing Active Surveillance After Chemoradiation
The NetherlandsStudy of Nivolumab, Ipilimumab, Relatlimab, and Daratumumab in Patients with Recurrent and Metastatic Colon Cancer
BelgiumStudy of Relatlimab, Nivolumab, and 5-Azacytidine for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Chemotherapy
GermanyStudy of Oncobax-AK with Immunotherapy for Patients with Advanced Non-Small Cell Lung Cancer or Renal Cell Carcinoma
BelgiumStudy on Immunotherapy with Nivolumab and Ipilimumab for Patients with Recurrent Head and Neck Cancer After Surgery
FranceStudy of Dabrafenib and Drug Combination for Patients with Metastatic Non-Clear Cell Kidney Cancer
DenmarkStudy on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors
BelgiumStudy on Nivolumab with Drug Combination for Patients with Intermediate Stage Liver Cancer
FranceStudy of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
